

**DISCLOSURE: FINANCIAL INTERESTS AND  
ARRANGEMENTS OF CLINICAL INVESTIGATORS**

TO BE COMPLETED BY APPLICANT

The following information concerning (see Summary Table), who participated as clinical investigators in the submitted study (see Summary Table), is submitted in accordance with 21 CFR part 54. The named individuals have participated in one or more of the following financial arrangements or hold financial interests that are required to be disclosed as follows:

*Please mark the applicable check boxes.*

- any financial arrangement entered into between the sponsor of the covered study and the clinical investigator involved in the conduct of the covered study, whereby the value of the compensation to the clinical investigator for conducting the study could be influenced by the outcome of the study;
- any significant payments of other sorts made on or after February 2, 1999, from the sponsor of the covered study, such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation, or honoraria;
- any proprietary interest in the product tested in the covered study held by the clinical investigator;
- any significant equity interest, as defined in 21 CFR 54.2(b), held by the clinical investigator in the sponsor of the covered study.

Details of the individuals' disclosable financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of clinical study results by any of the disclosed arrangements or interests.

NAME (b) (6)	TITLE (b) (6)
FIRM/ORGANIZATION Pfizer Inc.	
SIGNATURE (b) (6)	DATE 11/29/2021

**This section applies only to the requirements of the Paperwork Reduction Act of 1995.**

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 5 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to the address to the right:

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB Number."*

**Do NOT send your completed form to the PRA Staff email address below.**

Department of Health and Human Services  
Food and Drug Administration  
Office of Operations  
PRAStaff@fda.hhs.gov

<b>SUMMARY TABLE</b>	
<b>SIGNIFICANT PAYMENTS OF OTHER SORTS</b>	
<b>List of investigators</b>	<b>List of Protocol Numbers</b>
Dr. Nicola P. Klein	C4591001

<b>ANY SIGNIFICANT EQUITY INTEREST</b>	
<b>List of investigators</b>	<b>List of Protocol Numbers</b>
Dr. Jill A. Sangree	C4591001
Dr. Susan Edwards	C4591001

<b>DISCLOSURE DETAILS: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS</b>	
Product's Established Name:	bnt162

Name of Clinical Investigator or Related Entity:	Dr. Jill A. Sangree
Clinical Investigator ID:	281831
Product's Established Name:	bnt162
Study Name(s):	C4591001: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
Protocol Number(s):	C4591001
Center Number(s):	C4591001:1150
Disclosure Start Date(s):	C4591001:4/29/2020
Disclosure Cut-off Date(s):	C4591001:11/3/2021

DISCLOSURE TYPE: EQUITY SNAPSHOT SUMMARY *					
Investigator Name: Dr. Jill A. Sangree					
Protocol Number: C4591001					
Study Number	Disclosure Date	Publicly Held Company	Number of Shares	Value at Disclosure Date [USD]	Value Disclosed [USD]
C4591001	08/03/2020	Pfizer Inc.	(b) (6)	(b) (6)	(b) (6)

\* The Equity Snapshot Summary contains equity details disclosed by an investigator through one or more Financial Disclosure Forms completed from the start of the study through one year after the completion of the study. Please note the value disclosed is the value determined at the provided Disclosure Date and should not be accumulated with any other listed value.

Name of Clinical Investigator or Related Entity:	Dr. Nicola P. Klein
Clinical Investigator ID:	280164
Product's Established Name:	bnt162
Study Name(s):	C4591001: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
Protocol Number(s):	C4591001
Center Number(s):	C4591001:1126
Disclosure Start Date(s):	C4591001:4/29/2020
Disclosure Cut-off Date(s):	C4591001:11/3/2021

<b>DISCLOSURE TYPE: SIGNIFICANT PAYMENTS OF OTHER SORTS</b>				
<b>Investigator Name: Dr. Nicola P. Klein</b>				
<b>Protocol Number: C4591001</b>				
<b>Clinical Investigator or Related Entity</b>	<b>Check Number</b>	<b>Purpose</b>	<b>Payment Date</b>	<b>Amount [USD]</b>
KAISER RESEARCH FOUNDATION	0140480897	CLINICAL AND RESEARCH COLLABORATIONS	06/15/2020	<b>(b) (6)</b>
KAISER RESEARCH FOUNDATION	PAID	CLINICAL AND RESEARCH COLLABORATIONS	01/18/2021	
KAISER FOUNDATION RESEARCH INST	0140512813	CLINICAL AND RESEARCH COLLABORATIONS	07/26/2021	
<b>Payment exceeds threshold amount of \$24,999.00</b>			<b>Total:</b>	<b>(b) (6)</b>



Name of Clinical Investigator or Related Entity:	Dr. Susan Edwards
Clinical Investigator ID:	51458
Product's Established Name:	bnt162
Study Name(s):	C4591001: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
Protocol Number(s):	C4591001
Center Number(s):	C4591001:1006
Disclosure Start Date(s):	C4591001:4/29/2020
Disclosure Cut-off Date(s):	C4591001:11/3/2021

DISCLOSURE TYPE: EQUITY SNAPSHOT SUMMARY *					
Investigator Name: Dr. Susan Edwards					
Protocol Number: C4591001					
Study Number	Disclosure Date	Publicly Held Company	Number of Shares	Value at Disclosure Date [USD]	Value Disclosed [USD]
C4591001	11/19/2020	Pfizer Inc.	(b) (6)	(b) (6)	(b) (6)

\* The Equity Snapshot Summary contains equity details disclosed by an investigator through one or more Financial Disclosure Forms completed from the start of the study through one year after the completion of the study. Please note the value disclosed is the value determined at the provided Disclosure Date and should not be accumulated with any other listed value.